When there is substantial uncertainty about a new product’s expected value, stakeholders may have strong reasons to consider performance-based contracts. One of the hardest tasks in crafting such contracts is measuring the added value – the measurement needs to be clear but also simple to operationalize. A multi-stakeholder working group defined appropriate considerations when creating a value-based contract for new cancer therapies.